SILO PHARMA INC.近日宣布，其创新药物SPC-15已成功获得日本专利局颁发的专利授权通知书。这一重要进展标志着公司在亚太地区知识产权保护体系取得关键突破，为后续商业化布局奠定法律基础。
此次获批的专利涵盖SPC-15的核心化合物结构及特定医药用途，将有效构筑技术壁垒。公司首席执行官在声明中强调，日本作为全球主要医药市场之一，此项专利不仅强化了企业的国际知识产权矩阵，更将为潜在的区域合作与授权交易提供价值支撑。
目前SILO PHARMA正在推进SPC-15针对中枢神经系统疾病的临床前研究，跨国知识产权策略的持续落地，有望加速该候选药物在全球范围的开发进程。随着欧美及亚洲多地专利网络的完善，公司计划通过分层授权模式最大化资产价值，为长期增长注入新动能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.